CDMO

Sales & Marketing

Solution Spotlight: Accelerator Drug Development

Thermo Fisher Scientific’s Accelerator Drug Development is a suite of integrated services combining CDMO and CRO to streamline drug development.

News

Novo completes $16.5bn takeover of Catalent

Novo Holdings' $16.5bn takeover of US CDMO Catalent has been completed, after months of debate over potential antitrust issues.

News

Halozyme abandons its €2bn pursuit of Evotec

Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations

News

Nick Green, president and CEO of Avid Bioservices

Avid Bioservices to go private in $1.1bn private equity deal

Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part

R&D

Completing a successful tech transfer

Tech transfers can be difficult and every one is unique, but the right tips can help. Lannett CDMO's Grant Brock and Frantz Maignan weigh in.

News

Lonza adds biologics capacity with $1.2bn Roche deal

Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part o

Solution Spotlight: Accelerator Drug Development

Novo completes $16.5bn takeover of Catalent

Halozyme abandons its €2bn pursuit of Evotec

Avid Bioservices to go private in $1.1bn private equity deal

Completing a successful tech transfer

Lonza adds biologics capacity with $1.2bn Roche deal

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

CDMO

Editor's Picks